Interestingly, a recent study showed that immunomodulatory drugs such as thalidomide and its derivatives lenalidomide and pomalidomide act by disrupting the cereblon-CD147-MCT1 axis to exert their antitumor activity, highlighting the importance of the CD147-MCT1 complexes for survival of tumor cells [60]. The gene discussed is SLC16A1; the disease is neoplasm.